sfa 10:0

SFA 10:0, more commonly referred to as capric acid or decanoic acid, is a saturated fatty acid featuring a 10‑carbon aliphatic chain with no double bonds. Chemically classified as a medium‑chain fatty acid (MCFA), it differs from long‑chain saturated fatty acids in its digestion and metabolic fate. The IUPAC name for SFA 10:0 is decanoic acid, and it is sometimes called decylic acid in older biochemical literature. The term “capric” is derived from the Latin word "capra," meaning goat, reflecting its historical isolation from goat fat and the characteristic odor reminiscent of goats. As an MCFA, SFA 10:0 constitutes part of the total saturated fats found across a variety of foods, especially in certain plant oils like coconut and palm kernel oils, as well as in animal milk fats and cheeses. Unlike essential nutrients such as vitamins or minerals, there is no unique dietary requirement established for individual fatty acids like SFA 10:0. Instead, dietary recommendations typically focus on total fat and saturated fat intake. Health authorities, including the World Health Organization and national dietary guideline committees, advise that saturated fats collectively be limited within the context of a balanced diet (e.g., total saturated fat intake <10% of daily energy) to support cardiovascular health. Saturated fats are a major energy source in the diet and serve structural roles in cell membranes and signaling processes, although specific functional roles for individual saturated fatty acids such as SFA 10:0 are less well defined compared to essential polyunsaturated fatty acids. The structural features of SFA 10:0, particularly its medium length carbon chain, confer distinct metabolic properties. In the digestive tract, medium‑chain fatty acids are more water‑soluble than long‑chain counterparts. They are absorbed more rapidly and transported directly to the liver via the portal vein without the need for incorporation into chylomicrons for lymphatic transport. This means that once ingested, SFA 10:0 undergoes swift hepatic oxidation, providing a readily available energy substrate. This property has made capric acid and other MCFAs a focus of interest in ketogenic diets and clinical nutrition formulations for individuals with malabsorption syndromes. Although no deficiency syndrome is associated with SFA 10:0 itself, its intake contributes to overall saturated fat consumption, which is monitored for cardiovascular risk management.

Capric acid serves primarily as a metabolic substrate rather than an essential nutrient with unique biochemical functions. Its rapid absorption and transport to the liver support its role in energy metabolism, especially in settings where the body shifts toward ketone production, such as low‑carbohydrate or ketogenic diets. Medium‑chain fatty acids like SFA 10:0 can be oxidized swiftly in hepatic mitochondria, contributing to energy provision without extensive reliance on bile acids or micellar formation required for long‑chain fats. This characteristic underlies its use in specialized clinical nutrition where efficient energy delivery is needed. Beyond basic metabolism, emerging evidence suggests that medium‑chain fatty acids may exert specific effects on human physiology. Studies indicate that MCFAs can influence metabolic features and cognitive function, possibly through modulation of mitochondrial function and ketone production. Research reviews on dietary MCFAs report potential improvements in metabolic parameters and changes in gut microbiota composition, which may support overall host physiology. These effects appear to be mediated through shifts in microbial ecology and host immune signaling pathways. However, it is crucial to note that most research examines medium‑chain triglyceride (MCT) mixtures rather than isolated SFA 10:0, making it challenging to attribute effects exclusively to capric acid. Observational research on saturated fat intake and health outcomes indicates complex relationships. Some cohort studies suggest that not all saturated fatty acids exert identical effects on chronic disease risk profiles. For example, certain medium‑chain and odd‑chain saturated fats may show neutral or even inverse associations with metabolic outcomes compared to long‑chain saturated fats. Conversely, other data indicate that higher intakes of some saturated fatty acids might correlate with increased overweight or obesity risk, although causality remains uncertain. Broadly, dietary guidelines emphasize replacing saturated fats with unsaturated fats to reduce cardiovascular disease risk, but mechanistic and population heterogeneity suggests that individual fatty acids may differ in biological impact. Overall, while SFA 10:0 contributes to energy metabolism and may support ketogenic energy dynamics, its isolated benefits independent of total diet quality remain an active area of investigation.

Unlike vitamins and minerals, no formal Recommended Dietary Allowance (RDA) has been established for individual fatty acids such as SFA 10:0. Instead, public health nutrition guidelines focus on total fat and total saturated fat intake. The World Health Organization and national dietary guideline bodies recommend limiting saturated fat intake to less than 10% of total daily calories to support cardiovascular health. Some organizations and expert panels further suggest lowering saturated fat intake to 6% of calories for individuals at higher risk of heart disease. Because SFA 10:0 is one component of total saturated fats, it does not have a specific numeric daily requirement or deficiency threshold. Total dietary fat recommendations vary by age, sex, and life stage, but generally comprise 20%–35% of daily energy. Saturated fat comprises a subset of this total, and guidelines emphasize dietary patterns rich in polyunsaturated and monounsaturated fats from plant and marine sources. This focus arises from extensive epidemiological evidence linking higher saturated fat intake—particularly from processed meats and high‑fat dairy—to elevated LDL cholesterol and cardiovascular risk. Dietary patterns emphasizing replacement of saturated fats with unsaturated fats show more favorable lipid profiles and lower risk of cardiovascular events. While individual medium‑chain fatty acids like capric acid may be metabolically distinct, they are still counted within overall saturated fat intake goals. Factors influencing individual needs include energy requirements, metabolic health, activity level, and dietary preferences. For individuals following ketogenic diets, MCFAs including SFA 10:0 may be consumed at higher proportions to support ketosis and energy balance, but this should be undertaken with professional guidance due to implications for lipid profiles and long‑term health outcomes. In contrast, individuals with hyperlipidemia or existing cardiovascular disease may benefit from stricter saturated fat limits and increased intake of unsaturated fats. Pregnant and lactating women should focus on overall dietary quality and consult healthcare professionals to balance fat types within caloric needs, as no evidence suggests specific needs for individual SFAs. Ultimately, guidance for SFA 10:0 intake is embedded within broader saturated fat recommendations rather than unique numeric targets.

There is no recognized deficiency syndrome for individual fatty acids such as SFA 10:0, as the body can synthesize saturated fatty acids de novo from carbohydrate and other precursors. Essential fatty acid deficiency pertains specifically to certain polyunsaturated fats like linoleic acid and alpha‑linolenic acid, not saturated fatty acids. Consequently, clinical guidelines do not describe specific symptoms attributable to inadequate intake of SFA 10:0 alone. Instead, deficiency concerns center on essential fats and total energy intake. However, an extremely low total fat intake may lead to general signs of inadequate energy or essential fatty acid deficiency, including poor growth in children, dry skin, impaired thermoregulation, and hormonal imbalance. At‑risk groups for inadequate total fat or essential fatty acid intake include individuals with restrictive diets lacking energy density, people with malabsorptive disorders such as cystic fibrosis or pancreatic insufficiency, and those with eating disorders leading to very low caloric intake. In these settings, inadequate total fat can impact absorption of fat‑soluble vitamins (A, D, E, and K) and essential fatty acids, producing clinical manifestations such as coagulopathy, visual disturbances, and dermatitis. It is important to distinguish these broader deficiency syndromes from isolated shortages of specific saturated fatty acids like SFA 10:0, which do not have unique clinical signs. Healthcare providers may assess dietary intake patterns and blood lipid profiles in individuals with symptoms suggestive of inadequate fat intake or malabsorption. No specific laboratory test measures "capric acid deficiency," and levels of individual saturated fatty acids in blood typically reflect recent dietary intake rather than a functional deficiency state. Therefore, clinical signs prompting evaluation tend to relate to broader nutritional insufficiencies rather than lack of SFA 10:0 specifically. Public health guidance emphasizes balanced dietary fat intake, encompassing a range of fatty acids in proportions that support essential fat needs and overall metabolic health.

Foods containing SFA 10:0 contribute to total saturated fat intake. According to USDA nutrient data, the highest concentrations of capric acid are found in coconut and coconut‑derived products, certain dairy fats, and goat milk cheeses. Coconut milk ranks among the top sources, providing over 2.5 grams of SFA 10:0 per cup when canned and unsweetened. Shredded dried coconut and candied coconut bars also deliver substantial amounts per serving. Coconut oil, although a concentrated fat source, contains medium amounts of capric acid per tablespoon compared to coconut meat but contributes significantly due to its fat density. Dried unsweetened coconut yields over 1 gram per ounce, while dairy products such as hard goat cheese and light whipping cream provide nearly a gram or more per ounce or cup respectively. Other cheeses—including Parmesan, Feta, and Roquefort—contain smaller but measurable amounts of SFA 10:0, reflecting the presence of capric acid in milk fat. Palm kernel oil, similar to coconut oil in fatty acid profile, also provides capric acid, though overall consumption in typical diets may be lower due to usage patterns. Whole and high‑fat milks, butter, and cream contribute modest quantities of SFA 10:0 because dairy fats encompass a range of saturated fatty acids. Food preparation and processing influence content, and products like baked goods or processed foods containing coconut or dairy fats will provide variable amounts of SFA 10:0. Plant‑based foods outside the coconut/palm oil category generally contain negligible capric acid. When selecting foods, it is important to consider the broader nutritional context. While foods rich in capric acid deliver this specific fatty acid, they often contain significant total saturated fats and calories, which need to be balanced within overall dietary goals. For individuals seeking capric acid for metabolic or ketogenic purposes, MCT oil blends that standardize medium‑chain fatty acids may be used under professional guidance. Regardless of source, moderation and dietary pattern quality remain paramount for cardiovascular and metabolic health outcomes.

Medium‑chain fatty acids like SFA 10:0 are absorbed and metabolized differently than long‑chain saturated fats. In the digestive tract, SFA 10:0 does not require extensive micelle formation with bile acids; rather, it is absorbed directly into the portal circulation and transported to the liver for rapid oxidation. This pathway enables more immediate energy availability and distinguishes MCFAs from longer saturated fats that are incorporated into chylomicrons and transported via lymphatic routes to adipose and peripheral tissues. The hepatic uptake of capric acid supports its use in clinical nutrition for individuals with fat malabsorption and in ketogenic dietary strategies. Bioavailability of SFA 10:0 is influenced by food matrix and co‑consumed nutrients. For example, accompanying dietary fiber and complex carbohydrate slows gastric emptying and overall nutrient absorption kinetics, whereas high‑fat meals with mixed fatty acids may alter micellar dynamics for other fats without impeding direct portal uptake of medium chains. The presence of other fats, particularly long‑chain polyunsaturated fatty acids, may modulate postprandial lipid responses and influence blood lipid profiles. Additionally, genetic variation and gut microbiota composition can affect how individuals metabolize and utilize fatty acids, including MCFAs. While rapid absorption is a defining feature of SFA 10:0, excessive intake—especially isolated through MCT oil supplements—can lead to gastrointestinal discomfort, including bloating, cramps, and diarrhea, if introduced abruptly. Gradual incorporation into the diet and concurrent food intake can ameliorate these effects. Unlike essential fatty acids whose absorption may be competitively inhibited by high saturated fat diets, capric acid typically does not impede absorption of fat‑soluble vitamins when consumed in typical food amounts, though overall diet quality must ensure adequate intake of these nutrients.

Supplements providing medium‑chain fatty acids are widely available, often marketed as MCT oil blends that include capric acid (C10) alongside caprylic (C8) and lauric (C12) acids. These products are used in specific dietary strategies, particularly ketogenic and low‑carbohydrate diets, where rapid hepatic oxidation and ketone production are desired. Capric acid’s rapid metabolism offers a quick energy substrate that may support endurance and cognitive clarity, especially in the context of sustained carbohydrate restriction. However, the evidence base for isolated capric acid supplementation distinct from total MCTs is limited. Most studies evaluate combinations of medium‑chain fatty acids rather than pure SFA 10:0, making it difficult to ascribe observed outcomes solely to capric acid. Clinical scenarios in which MCT supplementation may be considered include malabsorption syndromes where efficient energy provision is needed, and in some neurodegenerative conditions where ketone availability might support neuronal metabolism. For healthy adults seeking weight management, the evidence suggests modest effects on satiety, energy expenditure, and body composition when MCTs replace other fats at equivalent calories, but long‑term outcomes require further evaluation. Individuals with metabolic conditions such as diabetes should approach MCT supplementation cautiously, considering overall lipid profiles and cardiovascular risk. Supplementation contraindications include individuals with liver disease, as the liver is the primary site of MCFA metabolism, and those with gastrointestinal disorders, where high doses can exacerbate symptoms. Pregnant and breastfeeding women, as well as children, should consult healthcare professionals before initiating MCT or capric acid supplementation due to limited safety data. Quality considerations entail choosing products with transparent labeling, third‑party testing, and clear concentration of medium‑chain fatty acids. Starting with low doses and taking supplements with meals can mitigate gastrointestinal discomfort. Ultimately, supplements may serve specific therapeutic or dietary goals, but they should not replace a balanced diet rich in whole foods and diversified fat sources.

There is no established Tolerable Upper Intake Level (UL) for individual saturated fatty acids such as SFA 10:0, and toxicity from naturally occurring dietary sources is rare when consumed within typical food patterns. However, excessive intake of saturated fats in general is associated with adverse cardiovascular outcomes, primarily through impacts on LDL cholesterol and related lipid biomarkers. Public health guidelines recommend limiting total saturated fat intake to less than 10% of total energy, with lower targets for individuals with established cardiovascular disease risk factors. Consuming medium‑chain fatty acids above recommended total fat thresholds may contribute to high caloric intake and unfavorable lipid profiles if not balanced with other macronutrients. Gastrointestinal intolerance, including nausea, cramps, and diarrhea, is the most commonly reported adverse effect of high supplemental doses of medium‑chain fatty acids, especially when consumed on an empty stomach or in large amounts. No specific organ toxicity has been documented for capric acid at dietary levels, but very high supplemental intake without medical oversight is not advised.

Specific drug interactions for individual SFA 10:0 are not well documented in clinical pharmacology literature. However, because medium‑chain fatty acids affect hepatic metabolism and bile acid dynamics, there is theoretical potential for interactions with medications that depend on lipid absorption and hepatic processing. For example, drugs that require bile acid‑mediated absorption could have altered bioavailability in the context of a diet very high in medium‑chain fats. Additionally, enzymes involved in fatty acid oxidation and drug metabolism (e.g., certain cytochrome P450 enzymes) might theoretically be modulated by high intake of medium‑chain fatty acids, although direct evidence is lacking. Patients taking medications with narrow therapeutic indices or those affecting lipid metabolism (such as fibrates or statins) should consult healthcare providers when considering high supplemental doses of MCTs to ensure no clinically relevant interactions occur. As always, any changes in diet or supplement use should be discussed with clinicians when on chronic medications.

Common Forms: MCT oil blends (liquid), capsules

Typical Doses: 1,000–3,000 mg capric acid per day in supplement context

When to Take: with meals to reduce gastrointestinal symptoms

Best Form: medium‑chain triglyceride (MCT) oil containing capric acid

⚠️ Interactions: potential modulation of lipid‑lowering medication effects, impact on fat‑soluble vitamin absorption if displacing other fats